GeneCentric Therapeutics Inc.
01/25/2023 | Press release | Archived content
2024 ASCO Genitourinary Cancers Symposium – Jan. 25-27, 2024 | San Francisco, CA
GeneCentric will be attending the 20th annual ASCO GU Symposium to be held January 25-27, 2024 in San Francisco, CA. In addition to attending the meeting, we will also be presenting two posters highlighting our ongoing work to develop novel RNA-based diagnostic tests for patients with bladder cancer. Please reach out ([email protected]) if you would like to schedule a 1:1 meeting with our team. Learn more and register here. https://conferences.asco.org/gu/attend
Posters:
Poster Session B (Urothelial Carcinoma): Abstract 549, Poster Board D20 - Development of a novel RNA-based immune checkpoint inhibitor response signature (ICI-PRS) that avoids standard-of-care (SOC) prognostic signal for use in patients with urothelial cancer (UC).
Poster Session B (Urothelial Carcinoma): Abstract 548, Poster Board D19 - Development of a novel RNA-based fibroblast growth factor receptor response signature (FGFR-PRS) for use in patients with urothelial cancer (UC).
GeneCentric Therapeutics Inc. published this content on January 25, 2023, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on March 17, 2026 at 05:28 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]